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or previous use of inhaled anticholinergics was not associated with a significant 
increased risk of AACG (active use: adjusted OR 1.32, 95% CI 0.83-2.10; non-active 
use: adjusted OR 1.13, 95% CI 0.72-1.75) compared to non-use, adjusting for use of 
other medications related to AACG. ConClusions: A relationship between the use 
of inhaled anticholinergics and the risk of AACG was not observed in this COPD pop-
ulation. However, the findings are limited due to the small sample size of the events.
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objeCtives: Chronic idiopathic/spontaneous urticaria (CIU) is a skin condition 
characterized by the presence of hives and angioedema lasting ≥ 6 weeks with no 
known cause. There is no specific ICD-9 code for CIU. This study aims to validate 
an ICD-9 based algorithm to identify patients with CIU to allow for epidemiologic 
research using administrative claims databases. Methods: Retrospective review 
of medical and billing records in 4 geographically-dispersed US allergy practices. 
Patients were eligible for inclusion if they met the either of these criteria: 1) ≥ 2 out-
patient visits with a diagnosis of idiopathic urticaria (ICD-9 708.1), other specified 
urticaria (708.8), or unspecified urticaria (708.9) ≥ 6 weeks apart, OR 2) ≥ 1 outpatient 
diagnosis of 708.1, 708.8 or 708.9 and 1 diagnosis of angioedema (995.1) ≥ 6 weeks 
apart. A random sample of patients known to have CIU were also included. Chart 
review was performed to collect information on ICD-9 codes, prescription medica-
tions, and clinical urticarial diagnoses abstracted from records of a random sample 
of eligible patients. Sensitivity and positive predictive value (PPV) were calculated. 
The study received central IRB approval. Results: There were 149 patients with a 
mean age of 41.1 years (SD: 20.8), 73.8% were female and 69.1% were white. For 104 
“true positive” patients, the mean (median) duration of CIU was 3.1(2.5) years. The 
claims algorithm had sensitivity of 71.1% and PPV of 90.4%. Using just the first algo-
rithm reduced PPV to 90.3% and sensitivity to 67.8%. Physicians most often identified 
CIU using the codes for idiopathic urticaria, unspecified urticaria and other urticarial 
conditions. ConClusions: PPV of 90.4% suggests patients identified using the 
tested ICD-9 algorithm are highly likely to have CIU. Sensitivity of 71.1% suggests 
that some patients with CIU would not be identified. Changes to the algorithm that 
increase sensitivity without decreasing PPV should be explored in future studies.
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objeCtives: Vitreomacular adhesion (VMA) can lead to pathologic traction and 
macular hole formation. In two phase 3 trials ocriplasmin induced a significant ana-
tomical response, as well as a significant functional response. The purpose of this 
analysis was to assess how the anatomic and visual function responses related to 
each other. Methods: An anatomic response was defined as complete non-surgical 
resolution of vitreomacular adhesion (VMA). Visual functional response was defined 
as either: non-surgical visual acuity improvement of ≥ 2 lines; or clinically mean-
ingful improvement in the visual function questionnaire (VFQ-25) composite score 
(> 3.6 points) or driving subscale (> 19.1 points). We defined complete responders 
as participants who improved both anatomically and functionally. Visual-function-
only responders, or anatomic-only-responders, were participants who improved 
in either category (but not both), and non-responders were participants without 
improvement in either category. We investigated the ocriplasmin effect for each 
of these response categories using generalized logit regression models with the 
non-responder group as baseline category. Results: The proportion of complete 
responders in the ocriplasmin group was 18.3%, versus 5.2% in the placebo group 
(p= 0.003). The proportion of visual-function-only responders was 36.8% and 29.0% 
(p= 0.0007); and the proportion of anatomic-only-responders was 10.2% and 5.2%, 
for ocriplasmin and placebo groups respectively (p< 0.0001). Ocriplasmin treatment 
produced a visual function response, either alone or in combination with an ana-
tomic response, in 55.1% of patients, compared to 34.2% of patients receiving pla-
cebo. ConClusions: The reason why visual function was larger than the anatomic 
response in the ocriplasmin treated group is not known, but the possibility of partial 
release of VMA positively affecting visual function warrants further investigation.
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objeCtives: Choroidal neovascularization (CNV) is the most common vision-
threatening complication associated with pathologic myopia (PM), or myopic CNV 
(mCNV). There is a lack of information on the epidemiology related to mCNV in 
the world and more so in Canada. This study aimed to determine the epidemi-
ology and the demographic and treatment characteristics of Canadian mCNV 
patients. Methods: Records from a longitudinal population-based database of 
more than 320,000 patients, collected from 75 physicians in Southwestern Ontario, 
Canada were analyzed between January 1, 2006 and December 31, 2011. Patient 
records were limited to subjects aged 18 years and older, and patients with at least 
one year of follow up. The clinical and demographics characteristics, medications, 
and resource use were reported in this study. A nested case-control study based on 
the final diagnosis of CNV secondary to PM was constructed within a PM cohort. In 
according to culture sensitivity reports is one of the rational utilization practices 
and one of the most important steps for combating multi drug resistance issue.
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objeCtives: To evaluate utilization patterns and health care costs among chil-
dren in Texas Medicaid diagnosed with otitis media (OM), and analyze the rela-
tionship between index antibiotic medication and prevalence of persistent OM 
(POM). Methods: A retrospective analysis of Texas Medicaid outpatient medical 
and prescription claims from July 2007 to August 2011 for beneficiaries (0-18 years) 
with an OM diagnosis (ICD-9: 381-382) and an associated antibiotic medication was 
conducted. POM was defined as having a subsequent OM diagnosis within 45 days 
after starting the index antibiotic medication. OM-related costs were compared 
across medications and logistic regression was used to evaluate POM likelihood by 
medication with demographics and costs as covariates. Utilization patterns will 
be described graphically using data visualization. Results: The study sample 
included 307,107 patients with a mean age of 3.0 years (SD= 3.8), a majority being 
male (51.9%), Hispanic (63.8%), and from an urban region (84.3%). The overall preva-
lence of POM was 19.3%. Total mean OM episode-related costs were 2.0 times higher 
for POM patients compared to non-POM patients, and the total OM-related cost to 
Medicaid was approximately $58 million. Four index antibiotics (noting their asso-
ciated POM prevalence) were studied: amoxicillin (19.0%), amoxicillin-clavulanate 
(21.2%), azithromycin (15.1%), and cefdinir (21.4%). The second least expensive index 
medication (azithromycin) had the lowest POM prevalence (15.1%) and the second 
lowest mean total OM-related costs ($194; SD= $313). Mean outpatient costs were 
similar between patients taking amoxicillin and cefdinir (the least and most expen-
sive medications, respectively), while amoxicillin-clavulanate and azithromycin 
patients’ outpatient costs were significantly higher (p< 0.01). Age, race, Texas region, 
index medication, and index medication cost category (low vs. high) were significant 
predictors (p< 0.01) of a POM episode. ConClusions: The data suggest different 
POM prevalence among index antibiotic medications, with POM patients accounting 
for a disproportionally higher portion of OM-related health care costs.
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objeCtives: To detect and clarify signals of serious skin reactions associated with 
acetaminophen, including Stevens-Johnson syndrome (SJS), toxic epidermal necrol-
ysis (TEN), and acute generalized exanthematous pustulosis (AGEP). Methods: 
Cases reported to FDA adverse event reporting system between 1997 and 2012 
were retrieved. The MedDRA Preferred Terms were used to define serious skin 
reactions. Acetaminophen products were identified by generic names. Empirical 
Bayes Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) was cal-
culated as disproportionality measure. Safety signals with EB05≥ 2 was considered 
a significant disproportional increase in event reporting of at least twice times 
higher than expected. Signals were reported for single-ingredient acetaminophen 
products, acetaminophen-containing combination products. Results: A total of 
1,295 reports of serious skin reactions were submitted for acetaminophen (592) 
and acetaminophen-containing products (703). Strongest serious skin event signals 
were detected for acetaminophen (EBGM= 5.03, EB05-EB95= 4.68-5.40) followed by 
acetaminophen-containing products (EBGM= 2.93, EB05-EB95= 2.75-3.13). Signals of 
SJS (n= 262, EB05= 3.29), TEN (n= 266, EB05= 7.15), and AGEP (n= 64, EB05= 5.55) were 
detected for acetaminophen. Except for SJS (n= 316, EB05= 1.94), signals of TEN 
(n= 304, EB05= 4.00) and AGEP (n= 83, EB05= 3.68) were detected for acetaminophen-
containing products. ConClusions: Treatment with acetaminophen might be 
associated with risks of serious skin reactions, including SJS, TEN, and AGEP. Patients 
should discontinue acetaminophen and seek medical attention when signs and 
symptoms of skin reactions occur. Signal evaluation measures are required to fur-
ther characterize the dermal risk profile of acetaminophen.
PSS2
riSk of acute angle-cloSure glaucoma aSSociated With inhaled 
anticholinergic agentS in a coPd PoPulation
Lee W.J., Lee T.A.
University of Illinois at Chicago, Chicago, IL, USA
objeCtives: Several cases of acute angle-closure glaucoma (AACG) have been 
reported due to use of inhaled anticholinergics. This study aims to evaluate the 
association between use of inhaled anticholinergics and risk of AACG among a 
population with chronic obstructive pulmonary disease (COPD). Methods: A 
nested case-control study was conducted among a cohort of subjects with new 
use of COPD medications in the IMS Lifelink Health Databases from Jan 1st 2005 to 
Dec 31st2011. Cases were identified as those with a new diagnosis of AACG (ICD-9 
365.22). For each case, up to 4 controls were randomly selected and matched on age, 
gender, geographic area, prevalent glaucoma, and cohort entry year and quarter 
using incident-density sampling. Conditional logistic regression was used to com-
pute the odds ratio (OR) and 95% confidence interval (CI) for active and previous 
use of inhaled anticholinergics. Active use was defined as concurrent use of inhaled 
anticholinergics on the event date. Previous use was defined as patients receiving 
prescription of inhaled anticholinergics one year prior to the event date. Results: 
The study cohort was comprised of 231,256 patients with a COPD diagnosis and 
first-use of COPD medications. The average age was 70.2 years old and 45.6% were 
males. A total of 261 cases with AACG were matched to 1,016 controls. Active use 
